@article{Edirappuli_Bedowes_2019, title={Effects of Various Treatment Regimens on the Survival of HER2-positive Breast Cancer Patients with Brain Metastasis }, volume={6}, url={https://physicianjnl.net/index.php/phy/article/view/29}, DOI={10.38192/1.6.1.c12}, abstractNote={<p>Overexpression of HER2 (human epidermal growth factor receptor 2) occurs in around 20% of breast cancers. This particular subtype is known to be very aggressive and had the worst prognosis prior to the introduction of targeted therapy. The development of anti-HER2 therapies such as trastuzumab and pertuzumab has shown to dramatically improve the prognosis of patients with HER2-positive breast cancer.</p>}, number={1}, journal={The Physician}, author={Edirappuli, Shantal and Bedowes, Emma}, year={2019}, month={Nov.}, pages={c12} }